CMC Due Diligence for Accelerated Biologic Drug Development and Manufacturing
The growing trend of partnerships between small biotech companies and CDMOs makes the need for conducting CMC due diligence increasingly important.
With the biopharmaceutical business model undergoing rapid transformation as the result of disruptive new platform technologies and the need for accelerated biopharmaceutical development growing globally, clinical-stage therapeutic companies are facing complex challenges. A growing trend of partnerships between small biotech companies and CDMOs is also making it increasingly important to conduct CMC due diligence.
Read this article in BioPharm International's Outsourcing Resources 2019 eBook.
Article Details
BioPharm International
eBook: Outsourcing Resources 2019
April 2019
Pages: 4–11
Citation
When referring to this article, please cite it as Y. Ding et al., "CMC Due Diligence for Accelerated Biologic Drug Development and Manufacturing," BioPharm International's Outsourcing Resources eBook (April 2019).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
